drugset / Trial / NCT07285304

A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

NCT07285304

Phase 3 Recruiting 300 enrolled Taisho Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

A clinical study to evaluate the long-term safety and efficacy of TS-172 in hyperphosphatemia patients on hemodialysis.

Timeline

Start
2025-12-01
Primary completion
2027-07-31
Completion
2027-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject TS-172 Unknown 20 mg Oral
Subject TS-172 Unknown 60 mg Oral

Indications